Arbutus Settles Litigation, Terminating Acuitas’ Rights to LNP Technology
February 22, 2018 16:35 ET
|
Arbutus Biopharma Corporation
Acuitas has No Further Rights to Use or Sublicense Arbutus LNP TechnologyArbutus Consolidates LNP Patent Estate Enabling RNAi, mRNA, and Gene-editing Therapeutics VANCOUVER, B.C. and WARMINSTER, Pa.,...
Arbutus Enters Exclusivity Agreement with Roivant Sciences
February 14, 2018 20:50 ET
|
Arbutus Biopharma Corporation
VANCOUVER, British Columbia and WARMINSTER, Pa., Feb. 14, 2018 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq:ABUS), an industry-leading Hepatitis B Virus (HBV) therapeutic solutions...
Arbutus Announces Departure of Chief Financial Officer; Appoints Interim CFO
February 13, 2018 21:36 ET
|
Arbutus Biopharma Corporation
VANCOUVER, British Columbia and WARMINSTER, Pa., Feb. 13, 2018 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq:ABUS), an industry-leading Hepatitis B Virus (HBV) therapeutic solutions...
Arbutus Consolidates HBV Business Around Warminster, PA Site
February 08, 2018 08:30 ET
|
Arbutus Biopharma Corporation
VANCOUVER, British Columbia and WARMINSTER, Pa., Feb. 08, 2018 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq:ABUS), an industry-leading Hepatitis B Virus (HBV) therapeutic solutions...
Arbutus Announces Closing of the Second Tranche of a $116M Strategic Investment from Roivant Sciences
January 16, 2018 08:30 ET
|
Arbutus Biopharma Corporation
VANCOUVER, British Columbia and WARMINSTER, Pa., Jan. 16, 2018 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq:ABUS), an industry-leading hepatitis B virus (HBV) therapeutic solutions...
Arbutus Announces Presentations at HepDART 2017
November 27, 2017 09:00 ET
|
Arbutus Biopharma Corporation
VANCOUVER, British Columbia and WARMINSTER, Pa., Nov. 27, 2017 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq:ABUS), an industry-leading Hepatitis B Virus (HBV) therapeutic solutions...
Arbutus’ LNP Licensee Alnylam Initiates Rolling Submission of New Drug Application (NDA) to U.S. Food and Drug Administration (FDA) for Patisiran
November 16, 2017 13:40 ET
|
Arbutus Biopharma Corporation
VANCOUVER, B.C. and WARMINSTER, Pa., Nov. 16, 2017 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq:ABUS), an industry-leading Hepatitis B Virus (HBV) therapeutic solutions company,...
Arbutus’ LNP Licensee Alnylam Receives Accelerated Assessment of Patisiran from European Medicines Agency (EMA)
November 13, 2017 17:22 ET
|
Arbutus Biopharma Corporation
VANCOUVER, British Columbia and WARMINSTER, Pa., Nov. 13, 2017 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq:ABUS), an industry-leading Hepatitis B Virus (HBV) therapeutic solutions...
Arbutus Announces Corporate Update and Third Quarter 2017 Financial Results
November 02, 2017 16:00 ET
|
Arbutus Biopharma Corporation
Strategic Investment from Roivant Extends Cash RunwayCombination Study for ARB-1467 Starting in 4Q17Company to Host a Corporate Update Conference Call Today at 4:15 PM ET VANCOUVER, British Columbia...
Arbutus Announces Conference Call to Provide a Corporate Update and Third Quarter 2017 Financial Results
October 31, 2017 18:16 ET
|
Arbutus Biopharma Corporation
VANCOUVER, British Columbia and WARMINSTER, Pa., Oct. 31, 2017 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq:ABUS), an industry-leading Hepatitis B Virus (HBV) therapeutic solutions...